Discordance of clinical symptoms and electrophysiologic findings in taxane plus platinum-induced neuropathy. Issue 2 (1st February 2007)

• Record Type: Journal Article
• Authors: Pan, Y.; Kao, M.-S.
• Is Part Of: International journal of gynecological cancer. Volume 17:Issue 2(2007)
• Page Start: 394
• Page End: 397
• Publication Date: 2007-02-01
• Subjects: carboplatin -- docetaxel -- neuropathy -- nerve conduction study -- paclitaxel; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1111/j.1525-1438.2006.00766.x
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Paclitaxel combined with carboplatin is currently accepted as the first-line treatment for ovarian carcinoma, frequently associated with neuropathy. Due to its frequent association with neuropathy, combination of docetaxel and carboplatin has been suggested as an alternative. A 47-year-old woman developed paresthesia after the first cycle of paclitaxel/carboplatin for ovarian cancer. Her nerve conduction study (NCS) showed only sural neuropathy after completion of six cycles, which returned to normal in 6 months. She had fewer neuropathy symptoms when treatment was changed to docetaxel/carboplatin for recurrent cancer. NCS revealed generalized sensory neuropathy following docetaxel/carboplatin treatment, which normalized after 12 months. Our observation indicated that there is a disparity between clinical symptoms and electrophysiologic examination in taxane-induced neuropathy. Although docetaxel was tolerated well by the patient, evidence of generalized sensory neuropathy was present in NCS